1. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.
2. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection Recommendations for a Public Health Approach, Second edition. Geneva, Switzerland: World Health Organization; 2016.
3. Xie D, Yao C, Wang L, Min W, Xu J, et al. (2010) An albumin conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54: 191–6.
4. Chong H, Yao X, Zhang C, Cai L, Cui S, et al. (2012) Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 7: e32599.
5. Zhang H, Jin R, Yao C, Zhang T, Wang M, et al. (2016) Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther 13: 8.
6. Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjectscombined with clinical study and simulation results. Xenobiotica 2017; 47:133–143.
7.  
8. Su B, Yao C, Zhao QX, Cai WP, Wang M, et al. (2020) Efficacy and safety of the long-acting fusioninhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J 2020; US Department of Health and Human Services guidelines.
9. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, et al. (2013) Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther  18: 867–76.
10. Chen S, Han Y, Song XJ (2020) Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients. Infect Dis Poverty 9: 75.
11. EACS Guidelines version 8.0, October 2015.
12. Kontorinis N, Dieterich D (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23: 173-82.
13. Knoll B, Vento S, Temesgen Z (2008) Etravirine. Drugs Today (Barc) 44: 23-33.
14. Rivero A, Mira J, Pineda J (2007) Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 59: 342-6.
15. S Brück, S Witte, J Brust (2008) “Hepatotoxicity in patients prescribed efavirenz or nevirapine,” European Journal of Medical Res 13: 343–8.
16. MS Sulkowski, DL Thomas, SH Mehta, RE Chaisson, RD Moore (2002) “Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections,” Hepatology, 35: 182–9.
17. Kolakowska A, Maresca AF, Collins IJ (2019) Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis 11: 372-87.
18. Wenning LA, Hanley WD, Brainard DM (2009) Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 53: 2852–6.
19. Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, et al. (2007) E ect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 51: 3104-10.
20. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, et al. (2011) Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother 55: 3195-200.
21. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD, et al. (2004) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Aids 18: 2277-84.
22. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, et al. (2006) Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61: 791-4.
23. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-52.
24. Manosuthi W, Wiboonchutikul S, Sungkanuparph S (2016) Integrated therapy for HIV and tuberculosis. AIDS Res Ther 13: 22.
25. Jackson Mukonzo, Eleni Aklillu, Vincent Marconi, Raymond F. Schinazi (2019) Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals, Int J Infectious Dis 83: 98-101.